Comparison of Bone Mineral Density and Markers of Bone Turnover in Osteoporotic Women after 6-Month Treatment with Alendronate or Bazedoxifene: A Randomized Controlled Trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: In a randomized controlled trial, we compared the bone mineral densities (BMDs) and blood markers of bone turnover during short-term treatment of osteoporotic women with bisphosphonate alendronate or bazedoxifene, a selective estrogen receptor modulator. Methods: Ten and eleven patients were randomized to the alendronate and bazedoxifene groups, respectively. BMDs were measured before and after 6 months of treatment. Blood tests were used to measure the levels of osteocalcin (OC), C terminal telopeptide of type I collagen (CTX), vitamin D3, and parathyroid hormone pretreatment and after 3 and 6 months of treatment. The variables were compared statistically. Results: The alendronate group showed decreases in blood levels of both OC and CTX during the study period (P<0.001 and P=0.002, respectively), while the bazedoxifene group had a decrease only in OC levels (P=0.012). After 6 months of treatment, BMDs significantly increased in the alendronate group at multiple bone sites, including the L1–4 lumbar vertebrae, femur trochanter, and total femur. However, there was no significant increase in BMD in the bazedoxifene group. BMDs were not significantly different between the 2 groups. Conclusions: Patients treated with alendronate showed more rapid suppression of markers of bone turnover and higher BMD than those treated with bazedoxifene during a short-term regime. Considering the effects and complications of each medication, the relationship between bone turnover rate and bone quality will need to be investigated in future studies.
Abstract
Background: In a randomized controlled trial, we compared the bone mineral densities (BMDs) and blood markers of bone turnover during short-term treatment of osteoporotic women with bisphosphonate alendronate or bazedoxifene, a selective estrogen receptor modulator. Methods: Ten and eleven patients were randomized to the alendronate and bazedoxifene groups, respectively. BMDs were measured before and after 6 months of treatment. Blood tests were used to measure the levels of osteocalcin (OC), C terminal telopeptide of type I collagen (CTX), vitamin D3, and parathyroid hormone pretreatment and after 3 and 6 months of treatment. The variables were compared statistically. Results: The alendronate group showed decreases in blood levels of both OC and CTX during the study period (P<0.001 and P=0.002, respectively), while the bazedoxifene group had a decrease only in OC levels (P=0.012). After 6 months of treatment, BMDs significantly increased in the alendronate group at multiple bone sites, including the L1–4 lumbar vertebrae, femur trochanter, and total femur. However, there was no significant increase in BMD in the bazedoxifene group. BMDs were not significantly different between the 2 groups. Conclusions: Patients treated with alendronate showed more rapid suppression of markers of bone turnover and higher BMD than those treated with bazedoxifene during a short-term regime. Considering the effects and complications of each medication, the relationship between bone turnover rate and bone quality will need to be investigated in future studies.
참고문헌 (13)
- Silvia Migliaccio, "The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis", Clinical Interventions in Aging, 2(1), pp.55~64 (2007), Informa UK Limited[DOI]
- Patrick Garnero, "Bone markers in osteoporosis", Current Osteoporosis Reports, 7(3), pp.84~90 (2009), Springer Science and Business Media LLC[DOI]
- Dual energy X ray absorptiometry for bone mineral density and body composition assessment, "International Atomic Energy Agency", International Atomic Energy Agency, ~, pp.IAEA Human Health Series No. 5 (2011)
- Natalia O Kuchuk, "Vitamin D Status, Parathyroid Function, Bone Turnover, and BMD in Postmenopausal Women With Osteoporosis: Global Perspective", Journal of Bone and Mineral Research, 24(4), pp.693~701 (2009), Wiley[DOI]
- Natasha Jordan, "Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women", Clinical Interventions in Aging, 1(4), pp.377~387 (2006), Informa UK Limited[DOI]
- Lars Rejnmark, "New and Emerging Antiresorptive Treatments in Osteoporosis", Current Drug Safety, 6(2), pp.75~88 (2011), Bentham Science Publishers Ltd.[DOI]
- Peter R. Ebeling, "Role of biochemical markers in the management of osteoporosis", Best Practice & Research Clinical Rheumatology, 15(3), pp.385~400 (2001), Elsevier BV[DOI]
- Meghan G Donaldson, "Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial", Journal of Bone and Mineral Research, 27(8), pp.1804~1810 (2012), Wiley[DOI]
- Stuart L Silverman, "Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial", J Bone Miner Res, 23(12), pp.1923~1934 (2008), Wiley[DOI]
- N. H. Bjarnason, "Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis", Osteoporosis International, 12(11), pp.922~930 (2001), Springer Science and Business Media LLC[DOI]
- 이서영, "The Effects of Low-Dose Bisphosphonate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Patients With Osteoporosis", Annals of geriatric medicine and research, 20(3), pp.131~136 (2016), 대한노인병학회[DOI]
- Yoshitomo Saita, "Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications", Therapeutic Advances in Chronic Disease, 6(4), pp.185~193 (2015), SAGE Publications[DOI]
- Alexandra G. Ellis, "Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women", Current Medical Research and Opinion, 30(8), pp.1617~1626 (2014), Informa Healthcare[DOI]